{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-001236","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2024-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.424996+00:00","generated_at":"2026-05-31T21:42:15.131749+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vivani to start LIBERATE-1 study of GLP-1 implant for obesity in Q4 2024","bullets":["NPM-115 is a 6-month exenatide implant for chronic weight management in obese/overweight patients.","LIBERATE-1: 24 patients randomized to implant, Bydureon BCise, or semaglutide for 9 weeks.","Study expected to begin Q4 2024 in Australia; data projected in 2025.","FDA cleared IND for NPM-119 (type 2 diabetes) in June 2024; company prioritized NPM-115.","Company plans to use Australian R&D incentives to defray trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-001236","json":"https://secwatch.observer/filing/0001753926-24-001236.json","markdown":"https://secwatch.observer/filing/0001753926-24-001236.md","text":"https://secwatch.observer/filing/0001753926-24-001236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624001236/0001753926-24-001236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624001236/g084331_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:42:15.131749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}